Hayfin today announces that, through its Private Equity Solutions strategy, it is acting as lead investor, together with Eurazeo, in the €220 million Continuation Fund raised by 21 Invest France to support the next phase of its ownership of ProductLife Group (“PLG”).

PLG is a global expert in regulatory affairs and compliance consulting for the healthcare industry. Serving more than 1,000 clients ranging from pharmaceutical companies, biotech and medtech companies, the group covers the entire lifecycle of pharmaceutical products, from development to post-marketing vigilance, across more than 150 countries. The company has expanded rapidly, driven by double-digit organic growth and 16 acquisitions in nine countries since 2020.

In addition to its management team, which is reinvesting significantly, PLG will be jointly controlled by Oakley Capital and 21 Invest France, which is reinvesting through its sixth fund vintage and the newly established Continuation Fund led by Hayfin and Eurazeo. Other investors are joining in syndication.

Gonzalo Erroz, Managing Director, Private Equity Solutions at Hayfin, commented: “We are delighted to partner with 21 Invest France to help support the continued growth of PLG at an exciting time for the business, as it seeks to expand its global presence and offering. The Continuation Fund will provide PLG with substantial resources to execute organic growth initiatives and pursue strategic acquisitions.”

Severin de Mortemart, Director, Private Equity Solutions at Hayfin, added: “This transaction further adds to our teams strong track record of identifying and supporting established sponsors in local markets on the continued growth trajectory of marquee assets in Hayfin’s core sectors of focus.”